Our research lab is situated in the Robert Bosch Center for Tumor Diseases (RBCT). RBCT is a newly established translational cancer research institute located at the Robert Bosch Health Campus in Stuttgart, Germany, in direct proximity to the Robert Bosch Hospital (RBK). As an integral part of the National Center for Tumor Diseases (NCT) South West and the Comprehensive Cancer Center Tübingen-Stuttgart, RBCT is exclusively dedicated to innovative cancer research and treatment.
Our group focuses on unraveling complex gene regulatory networks that govern the pathogenesis of hematological malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We employ cutting-edge techniques such as NGS-coupled multiomics, high-throughput screening, and gene interference or editing on tumor cell lines, primary patient samples, and mouse tumor models. Our primary research goal is to identify novel molecular biomarkers and therapeutic targets/approaches in human MDS or AML.
Robert-Bosch-Krankenhaus GmbH